Abbott and ChemDiv Research Institute to develop new drugs for Russian market
Will also conduct research into new treatments for viral diseases with Intellectual Dialog
Abbott Laboratories has agreed with the ChemDiv Research Institute (CDRI) in Moscow to launch several r&d projects in Russia to broaden therapeutic opportunities for the patients and to contribute to building an innovative pharmaceutical industry in the country.
CDRI is an integrated CRO subsidiary of ChemDiv of San Diego, CA, US, established at the ChemRar High Tech Centre in Moscow, with subsidiaries in Russia and Ukraine.
The first collaboration between CDRI and Abbott will focus on creating new forms of Abbott’s pharmaceuticals to increase compliance and decrease medicine intake. The partners say these goals will be accomplished by developing new technologies and by introducing new formulations.
In addition, there are ongoing discussions between CDRI and Abbott regarding several programmes for joint development of small molecule medicines.
ChemRar’s r&d company, Intellectual Dialog, has also launched a research project with Abbott aimed at the prevention and treatment of selected viral diseases affecting children and the elderly.
Nikolay Savchuk, chairman at CDRI, said: ‘CDRI is actively involved in both developing new molecules and improving existing drugs, covering the full cycle from pre-clinical development to manufacturing.
‘Our collaboration with Abbott will draw on the company’s expertise and technologies and Russia’s significant scientific potential to develop new products of the highest quality based on existing drugs.’
